Related Experiment Video
Updated: Aug 13, 2026

Measuring Local Anaphylaxis in Mice
Published on: October 14, 2014
Fatal cases of gabexate mesilate-induced anaphylaxis
Y Matsukawa1, S Nishinarita, S Sawada
1Department of Internal Medicine I, Nihon University School of Medicine, Tokyo, Japan. m-2000@mbk.sphere.ne.jp
Abstract:
Gabexate mesilate, ethyl-4-(6-guanidinohexanoyloxy) benzoate monomethanesulfonate (C16H23N3 O4CH4O3S: M.W. 417.48), is a synthetic protease inhibitor and was introduced for clinical use in 1978. It rarely induces anaphylaxis, and patients with gabexate mesilate-induced shock had been reported to survive with appropriate treatments including respiratory support. However, there were increasing reports on fatal cases in recent years: 6 cases have been reported to develop fatal anaphylaxis following dripping infusions of gabexate mesilate. All the fatal cases rapidly developed anaphylaxis (within 5 minutes), whereas 7 out of 11 in recovered cases developed it 5 or more minutes after the injection. Venous access should be kept for at least 30 minutes to prepare for and to treat this fatal reaction in patients receiving gabexate mesilate repeatedly.
Related Concept Videos
Allergic Reactions
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Drug Toxicity: Allergic Reactions
Allergic Reactions: Anaphylaxis

